Johnson & Johnson (JNJ)

US President Trump imposed 200% tariff on pharmaceuticals affecting US drug prices and supply chain, but analysts say it may not happen soon.

Artificial intelligence (AI) has become one of the most exciting and volatile sectors in the stock market. As companies like (NASDAQ:NVDA), (NASDAQ:PLTR), and (NASDAQ:TSLA) drive innovation in everything from chips to autonomous software, retail and institutional investors alike are piling into AI stocks at record levels. But

In a market where volatility creates both fear and opportunity, income-focused investors are increasingly turning to a lesser-known but powerful strategy: selling cash-secured puts. This options strategy not only allows investors to generate steady income, but it also provides a disciplined way to potentially acquire stocks at prices below current

With solid Q2 results and 2025 guidance increases, Wall Street is upgrading these four stocks. Analysts now see palpable upside in one streaming stalwart.

AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.

Apple expands retail presence in Saudi Arabia by launching online store and app, offering personalized support and localized experience.

Three dividend-paying stocks with high yields present an opportunity for significant passive income but a potentially high dividend payout ratio.

These S&P 500 dividend stocks have fallen by up to 33% and are best buys now.

Wall Street rose to new heights during the week amid strong earnings and solid economic data. Meanwhile, Fed rate cut debate heats up.

This week's M&A news includes strategic pivots and stumbles galore, with updates from WK Kellogg, Matador Restaurant and Windsurf.

Shares of Johnson & Johnson broke out of a classic ascending triangle pattern. They have since stalled out at resistance.

Three dividend stocks stand out in July, offering reliable income, attractive yields, and strong fundamentals to help investors navigate market volatility

Johnson & Johnson earnings came in 3% higher than consensus. The company's operating leverage was "slightly diluted by higher tax."

Investors monitor shifting market dynamics and consumer behavior post-pandemic, with Sarat Sethi sticking with Johnson & Johnson amid a positive earnings report. Stephen Weiss picks iShares Bitcoin Trust ETF and Joseph Terranova chooses Intercontinental Exchange, with Piper Sandler raising price target for ICE. Johnson & Johnson's FY2025 earnings guidance rose, while iShares Bitcoin Trust ETF and Intercontinental Exchange shares saw varied movement.

Johnson & Johnson hinted at leveraging tariff delays to maintain its outlook; however, Jim Cramer credited the performance to lower tariffs.

Powell Panic, Pharma Power & a PEW Parade: Wall Street’s Wild Wednesday

Analysts highlighted momentum in oncology and MedTech, with Wells Fargo calling the second-half growth acceleration “achievable” and Morgan Stanley noting visibility risks from drug pricing and tariff policy.

U.S. stocks moved higher today, with the Dow Jones gaining more than 200 points, or 0.5%, to close at 44,254.78.